Critique of Entropic Brain and Irruption Theories in Psychedelic Neuroscience

Critical Review of Neural Entropy Theories in Psychedelic Science

A November 2026 peer-reviewed paper (OpenAlex W7225916714) delivers a substantive critique of two prominent frameworks in psychedelic neuroscience: the Entropic Brain Hypothesis (EBH) and Irruption Theory (IT). Both models have shaped recent thinking about how psychedelic compounds alter consciousness by increasing neural entropy, a measure of unpredictability or disorder in brain activity. The paper argues that these frameworks face distinct but significant conceptual challenges, particularly regarding their claims to bridge objective brain metrics with subjective experience.

Mechanisms and Conceptual Context: Entropy, Subjectivity, and the Intelligibility Problem

The Entropic Brain Hypothesis, introduced by Carhart-Harris and colleagues in the early 2010s, posits that psychedelic states are marked by increased neural entropy, which purportedly correlates with more flexible, less constrained patterns of consciousness. Irruption Theory, a more recent entrant, acknowledges the philosophical difficulty—termed the "intelligibility problem"—of connecting physical brain states to first-person experiences, and attempts to sidestep it while still searching for neural signatures of consciousness.

The new critique highlights a key issue: EBH may overstate its case by suggesting that statistical measures of neural entropy directly reflect the felt uncertainty or vividness of subjective experience. This leap, the author argues, risks conflating the mathematical properties of neural signals with the qualitative texture of consciousness. Irruption Theory, while more philosophically cautious, still assumes that neural entropy can serve as an indirect but reliable marker of mental activity, a stance the paper finds problematic given the persistent gap between objective measurements and subjective reports.

Implications for Psychedelic Research Design and Interpretation

The critique has immediate implications for ongoing and future psychedelic research, particularly studies employing neuroimaging (such as fMRI or MEG) to assess the effects of compounds like psilocybin, LSD, or DMT. Many recent trials, including those registered with ClinicalTrials.gov (e.g., NCT03866174), have used neural entropy metrics as key outcome measures or mechanistic endpoints. If, as the critique suggests, entropy measures are not straightforward proxies for subjective experience, researchers must exercise greater caution in interpreting their findings and in designing studies that seek to link neural and experiential data.

• Trial design: The critique suggests that protocols relying on entropy as a primary endpoint may need to supplement or reconsider their outcome measures, perhaps integrating richer qualitative assessments or alternative neurobiological markers.
• Interpretation of results: The paper underscores the risk of over-interpreting correlations between entropy and subjective reports, especially in regulatory or clinical contexts where mechanistic clarity is required.
• Philosophical underpinnings: The debate reopens foundational questions about the limits of reductionist neuroscience in explaining consciousness, which may influence grant funding, peer review, and publication standards.

Risks, Unknowns, and a Real-World Failure Mode

One practical risk is that overreliance on neural entropy as a mechanistic explanation could lead to misleading claims about the efficacy or safety of psychedelic interventions. For example, a clinical trial might report increased neural entropy following psilocybin administration and infer enhanced therapeutic potential, without adequately substantiating the link to meaningful subjective or clinical outcomes. This failure mode has already surfaced in early-stage trials where entropy metrics were prioritized over patient-reported outcomes or functional measures.

Another unknown is whether alternative computational or systems neuroscience approaches might better capture the complexity of psychedelic states without succumbing to the same conceptual pitfalls. The critique points to the need for interdisciplinary collaboration, integrating phenomenology, philosophy of mind, and advanced neuroimaging.

Looking Forward: Toward More Robust Psychedelic Neuroscience

The paper’s arguments are likely to spur methodological and philosophical reflection across the psychedelic research community. Funders, ethics boards, and regulatory agencies may increasingly scrutinize the use of neural entropy as a mechanistic endpoint, demanding more rigorous justification and triangulation with subjective and behavioral data. The critique also highlights the importance of transparency in reporting both the strengths and limitations of neuroimaging-derived metrics.

As psychedelic science matures, the field may shift toward hybrid models that combine quantitative brain data with qualitative and experiential research, acknowledging the inherent challenges in bridging the subjective-objective divide. This shift could help avoid both overpromising and underexplaining the mechanisms by which psychedelics affect consciousness and mental health.

How we research / reviewed by Dr. Alex M. Carter, PhD (Neuroscience), on 2026-11-15. Primary sources: OpenAlex W7225916714, ClinicalTrials.gov NCT03866174, Carhart-Harris et al. (2014).